Neurological disorders affect approximately 42% of the global population, shaping the landscape of brain health for individuals and families alike.1 From multiple sclerosis (MS) to Alzheimer's disease and Parkinson's, these conditions present complex challenges to brain health that demand innovative solutions, comprehensive care and forward-thinking policies. Today, we stand at a pivotal moment where advances in science, technology and healthcare policy are converging to reshape how we understand, measure and support those living with neurological conditions.

42% stat | Sanofi

Affecting approximately 3m people worldwide, MS typically begins in young adulthood and gives rise to far-reaching consequences—impacting not only patients and their families but also generating a substantial socioeconomic burden across society.2 We recently supported an independently developed and researched Economist Enterprise study that examines the disability burden of MS across seven countries (France, Germany, Italy, Spain, Sweden, the United Kingdom and the United States), revealing critical gaps in how society measures, understands and manages MS disability—gaps that significantly impact patients, caregivers, healthcare systems and public health.3

"We need to fundamentally rethink how we measure what matters to patients and society. Without capturing the full economic burden, we're making healthcare decisions with incomplete information,” says Audrey Duval, MD, executive vice president, head of global corporate affairs at Sanofi. “Only by truly measuring what matters—including the full economic burden of disability—can health systems respond effectively to the complex challenges of neurological disorders, including MS.”

The truth is stark: people with MS typically manage an average of 14 symptoms simultaneously.4Although some may be visible, many—such as crushing fatigue, ‘brain fog’ and chronic pain—remain hidden from view. Perhaps most telling is that although 94% of MS patients experience fatigue,5 only 53% of neurologists routinely assess for it.6

What we can’t measure, we can’t manage

Widely utilised assessment tools focus primarily on physical symptoms—how well someone can walk, maintain balance or see—while overlooking cognitive challenges, emotional well-being and social functioning that profoundly affect quality of life.7 Similar gaps exist for other "invisible" symptoms such as cognitive difficulties, depression and pain—symptoms that profoundly affect daily life but often go unmeasured in clinical settings.

54%

of patients have access to occupational therapy, and just 59% can access mental health care.

Economist Enterprise’s research found that only 54% of patients have access to occupational therapy, and just 59% can access mental health care. Sexual and reproductive care is available to only 19% of patients—despite an overwhelming need among the many MS patients diagnosed during prime reproductive years.8

When healthcare systems focus solely on physical metrics, they fail to capture the full spectrum of neurological symptoms, leaving patients without appropriate care.9 Comprehensive approaches must integrate cognitive, emotional and social well-being alongside physical symptoms.

“True progress begins when we see the whole picture, not just the symptoms we can measure, but the ones we, as patients, can feel,” says Julie Stamm, 46, who has been living with MS for the last 19 years in the United States. “Only by acknowledging both the seen and unseen sides of disease can we create care plans that truly support the person, not just the condition.”

More than medical bills

The financial impact of MS is staggering, with annual economic burdens ranging from about US$57,000 to US$146,000 per person.10 The real cost extends far beyond medical bills, reaching into every aspect of daily life.

As disability advances, costs shift dramatically from direct healthcare expenses to indirect costs, with lost productivity and informal caregiving representing nearly three-quarters of total expenses in severe cases.11 Direct non-healthcare costs, such as home modifications, escalate from 1% in mild cases to 25% for those severely affected.

However, these figures likely underestimate the true economic burden. Current assessment models fail to capture crucial costs including out-of-pocket expenses (a recent World Health Organisation report found that one in four countries reported that most people with neurological disorders pay more than 50% out-of-pocket for care)12, long-term career disruptions, reduced lifetime earnings, early intervention value and intergenerational financial impacts. Costs for cognitive rehabilitation, fatigue management, workplace accommodations for invisible symptoms, and mental health services also go unmeasured. More sophisticated economic models are urgently needed13—ones that integrate patient-reported data, comprehensive caregiver burden measurements and longitudinal lifetime studies to provide a complete picture of societal costs.

Life interrupted

Without visible signs of disability, colleagues and employers may struggle to understand the need for accommodations such as flexible schedules or remote work options. Nearly 80% of people with severe MS are unable to work, compared with about 20% of those with mild MS, the Economist Enterprise research shows. Even those who maintain employment face challenges—absence from work escalates from an average of 32 days annually for mild MS to a staggering 163 days for those with severe MS.14

Nearly 80%

of people with severe MS are unable to work, compared with about 20% of those with mild MS.

What remains unmeasured are the qualitative impacts on career advancement and the economic ripple effects through organisations when experienced employees must reduce responsibilities or leave the workforce entirely.

Perhaps most overlooked is the caregiver burden. Approximately 82% of people with severe MS require support from informal caregivers, typically unpaid family members.15 Even among those with mild MS, one in five need informal care. Caregiving responsibilities for all neurological disorders translate into significant productivity losses, but current economic models fail to adequately capture the long-term impact on career, earnings, physical and emotional strain, and retirement implications for these care partners.

“These figures demonstrate why early intervention and comprehensive disability management must be global healthcare priorities, especially with a complete economic picture," says Sanofi’s Dr Duval.

Moving forward: every moment matters

Meaningful change for the future of brain health requires careful orchestration across multiple stakeholders, while maintaining the continuity necessary for ongoing patient care and research progress. Through sustained commitment to progress in both policy and practice, we can ensure that scientific advancements translate into real improvements in the lives of people with neurological disorders.

The path forward demands that we look beyond what's visible. Only by understanding and acknowledging the full spectrum of neurological conditions can we create meaningful support systems and treatments that address all aspects of these conditions—seen and unseen. For millions living with neurological disabilities, recognition of their complete experience isn't just about better treatment—it's about dignity, understanding and the opportunity to live for the moment, not the disease.

References
  • 1.
    World Health Organisation, Global status report on neurology, 2025.
  • 2.
    Walton C., King R., Rechtman L. et al., Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS (3rd edn.), Multiple Sclerosis Journal , 2020, Vol. 26(14), pp. 1816-1821.
  • 3.
    Economist Enterprise, Measuring What Matters; The critical gap in multiple sclerosis disability assessment, 2025.
  • 4.
    European Multiple Sclerosis Platform, Impact of Multiple Sclerosis Symptoms, 2025.
  • 5.
    ibid.
  • 6.
    Economist Enterprise, Measuring What Matters; The critical gap in multiple sclerosis disability assessment, 2025.
  • 7.
    Greenberg B., Giovannoni G., Hellwig K. et al, Gaps and discordance in assessment of PIRA identified between HCPs and people with MS: Results of international surveys, Multiple Sclerosis and Related Disorders , 2025.
  • 8.
    Economist Enterprise, Measuring What Matters; The critical gap in multiple sclerosis disability assessment, 2025.
  • 9.
    European Multiple Sclerosis Platform, Impact of Multiple Sclerosis Symptoms, 2025.
  • 10.
    Economist Enterprise, Measuring What Matters; The critical gap in multiple sclerosis disability assessment, 2025.
  • 11.
    ibid.
  • 12.
    World Health Organisation,Global status report on neurology, 2025.
  • 13.
    Bergemann R., Libanore A., Rudell K. et al., EE394 Redefining the Scope: The Urgent Need for Holistic Multiple Sclerosis Modeling in Health Economics, Value in Health, 2024, Vol. 27(6, Supp.), pp. S129-S130.
  • 14.
    Economist Enterprise, Measuring What Matters; The critical gap in multiple sclerosis disability assessment, 2025.
  • 15.
    ibid.